Elvia Cowan - Jan 1, 2023 Form 3 Insider Report for Vaxcyte, Inc. (PCVX)

Role
SVP, Finance and Principal Accounting Officer
Signature
Elvia Cowan, by /s/ Ron A. Metzger, Attorney-in-Fact
Stock symbol
PCVX
Transactions as of
Jan 1, 2023
Transactions value $
$0
Form type
3
Date filed
1/4/2023, 03:33 PM
Next filing
Mar 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PCVX Common Stock 0 Jan 1, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PCVX Stock Option (Right to Buy) Jan 1, 2023 Common Stock 140K $25.92 Direct F1
holding PCVX Stock Option (Right to Buy) Jan 1, 2023 Common Stock 15K $47.95 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/4 of the shares subject to the option shall vest on July 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
F2 1/48 of shares subject to the option vest on January 30, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.

Remarks:

SVP, Finance and Principal Accounting Officer